Health Care & Life Sciences » Biotechnology | Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
58.48 M
Public Float
42.85 M
Aimmune Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$3.63
Market Cap
$1.3 B
Shares Outstanding
62.49 M
Public Float
34.21 M

Profile

Address
8000 Marina Boulevard
Brisbane California 94005
United States
Employees -
Website http://www.aimmune.com
Updated 07/08/2019
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Financials

View All

Jayson Donald Alexander Dallas
President, Chief Executive Officer & Director
Gregory Behar
Director